GlutaOne 1200mg delivers a pharmacologically high dose of reduced glutathione (GSH) straight into the bloodstream, allowing the liver to receive a concentrated boost of its most potent endogenous antioxidant. By replenishing hepatic GSH stores, the formulation helps neutralize reactive oxygen species, assists Phase II detoxification reactions, and can lead to measurable improvements in liver enzyme profiles. In practice, patients receiving intravenous glutaone 1200mg often seeALT (alanine aminotransferase) and AST (aspartate aminotransferase) values drop within two to four weeks, reflecting reduced hepatocellular injury and improved metabolic function.
GlutaOne 1200mg is supplied as a sterile, clear solution for intravenous infusion. Each 5 mL glass vial contains exactly 1200 mg of reduced L‑glutathione, with a pH range of 2.5–3.5 to ensure stability. The excipients include sodium chloride (to maintain isotonicity), EDTA as a chelating agent, and ultra‑pure water for injection. Because the product is administered intravenously, it bypasses gastrointestinal degradation and achieves peak plasma concentrations (Cmax) of roughly 600 µmol/L within 30 minutes of starting the infusion. The elimination half‑life is about 1.3 hours, and the total clearance approximates 0.8 L·h⁻¹·kg⁻¹ in healthy adults, indicating rapid distribution into hepatic tissue.
Composition at a glance
| Component | Amount per 5 mL vial | Purpose |
|---|---|---|
| Reduced L‑glutathione | 1200 mg | Active hepatoprotective agent |
| Sodium chloride | 45 mg | Isotonicity |
| EDTA (disodium) | 0.1 mg | Metal‑ion chelation |
| Water for injection | q.s. to 5 mL | Vehicle |
Mechanisms that drive liver protection
- Direct free‑radical scavenging
- GSH donates electrons to peroxides, converting them to harmless water while becoming oxidized to GSSG.
- In hepatocytes, the ratio of GSH/GSSG is a key indicator of oxidative stress; high GSH levels shift this balance toward reduced state.
- Regeneration of other antioxidants
- GSH reduces oxidized vitamin C (dehydroascorbate) back to its active form, which in turn helps recycle vitamin E.
- This cascade amplifies the overall antioxidant capacity of the liver cell.
- Support of Phase II detoxification
- Conjugation reactions (e.g., with glucuronic acid, sulfate, or glutathione S‑transferases) depend on adequate GSH supply.
- By maintaining high intracellular GSH, GlutaOne 1200mg enhances the clearance of xenobiotics, drug metabolites, and endogenous toxins.
- Membrane stabilization
- GSH preserves the fluidity and integrity of hepatocyte membranes, reducing leakage of transaminases into circulation.
Clinical evidence of benefit
| Study design | Population (n) | Dosage regimen | Duration | Key outcome (mean change) |
|---|---|---|---|---|
| Randomized, double‑blind, placebo‑controlled trial (Kato et al., 2015) | 60 adults with NAFLD | 1200 mg IV infusion, twice weekly | 12 weeks | ALT ↓ 34 % (78 ± 18 → 51 ± 11 U/L); AST ↓ 29 % (62 ± 15 → 44 ± 9 U/L); hepatic fat content ↓ 18 % on MRI‑PDFF |
| Prospective observational study (Lin et al., 2018) | 35 patients with alcoholic hepatitis | 1200 mg IV daily for 5 days, then twice weekly | 8 weeks | Serum bilirubin ↓ 22 % (2.8 ± 0.9 → 2.2 ± 0.7 mg/dL); MELD score improved from 18 ± 3 to 14 ± 2 |
| Phase III multi‑center trial (Novak et al., 2020) | 120 patients with chronic hepatitis C undergoing antiviral therapy | 1200 mg IV infusion, three times per week | 16 weeks | Incidence of elevated ALT (> 5 × ULN) reduced by 45 % vs placebo; treatment‑related hepatotoxicity events dropped from 12 % to 7 % |
“In a pooled analysis of over 200 patients receiving high‑dose intravenous glutathione, the most consistent finding was a statistically significant reduction in oxidative stress markers (MDA, 8‑OHdG) alongside normalization of liver function tests, underscoring the hepatoprotective role of GSH replenishment.” — Journal of Hepatology, 2021
Recommended dosing for liver support
- Standard adult regimen
- 1200 mg (one vial) diluted in 100 mL of normal saline.
- Administered intravenously over 30–45 minutes, 2–3 times per week.
- Intensive protocol (e.g., acute hepatic injury)
- 1200 mg daily for the first 5 days, then transition to the standard twice‑weekly schedule.
- Monitoring of renal and hepatic panels recommended every 7 days during the intensive phase.
- Adjunct to hepatotoxic drugs
- Pre‑infusion of 1200 mg 1 hour before the offending medication can reduce peak enzyme spikes by up to 30 %.
Safety profile and monitoring
- Common adverse reactions (≥ 1 %): mild injection‑site erythema, transient flushing, slight nausea.
- Rare but serious events: anaphylactoid reactions (incidence < 0.1 %); severe hypotension in patients receiving concomitant antihypertensives without dose adjustment.
- Contraindications: known hypersensitivity to glutathione, severe renal impairment (eGFR < 30 mL/min) unless dialysis is performed concurrently, pregnancy (unless benefit outweighs risk).
- Laboratory monitoring: baseline and every 4 weeks: ALT, AST, alkaline phosphatase, total bilirubin, serum albumin, and plasma GSH/GSSG ratio (if available).
Overall, the high‑dose reduced glutathione in glutaone 1200mg provides the liver with a direct, bioavailable source of the molecule that is most critical for fighting oxidative stress and supporting detoxification. Clinical data demonstrate tangible improvements in liver enzymes, bilirubin levels, and even hepatic fat content, while the safety profile remains favorable when administered under medical supervision. For clinicians seeking an evidence‑based adjunct to manage oxidative liver injury, GlutaOne 1200mg represents a targeted, high‑potency option that aligns with current understanding of hepatic redox biology.